Daniel R Curtis

US Patent:

6741250, May 25, 2004

Filed:

Oct 17, 2001

Appl. No.:

09/982614

Inventors:

John L. W. Furlan - Belmont CA
Robert G. Hoffman - Fremont CA
Derek Fluker - San Jose CA
Karen L. Bechtel - San Jose CA
Katerina L. Shiffer - Milpitas CA
Venugopal Garimella - Sunnyvale CA
Daniel B. Curtis - Newark CA

Assignee:

Be Here Corporation - Fremont CA

International Classification:

G06T 1500

US Classification:

345427

Abstract:

Methods and apparatus for defining a view path through at least one wide-angle video stream and for creation of a resultant unwarped video stream responsive to the view path. Aspects of the invention allow an operator to monitor the wide-angle video stream(s) and select which portion of the wide-angle frame to unwarp in real-time. Further, the operator can stop the playback of the wide-angle video stream and dwell within a particular wide-angle frame to create special effects such as camera tilt, pan and zoom operations in a stop action situation.

US Patent:

7125687, Oct 24, 2006

Filed:

May 5, 2000

Appl. No.:

09/568942

Inventors:

Daniel Tim Curtis - South San Francisco CA, US
George Ross Francis - South San Francisco CA, US
Michael Christopher Ellis - South San Francisco CA, US
David Andrew Ruddy - South San Francisco CA, US
Sharmon Monique Nicoll - South San Francisco CA, US
Garth Joseph McGrath - South San Francisco CA, US

Assignee:

Exelixis, Inc. - So. San Francisco CA

International Classification:

C12P 21/06
C12N 5/00
C12N 15/00
A01N 43/04
A61K 31/715

US Classification:

435 691, 435325, 435455, 800 21, 514 44

Abstract:

The invention provides methods and compositions relating to pen polypeptides having pen-specific structure and activity, related polynucleotides and modulators of pen function. The invention provides isolated pen hybridization probes and primers capable of specifically hybridizing with natural pen genes, pen-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e. g. genetic hybridization screens for pen transcripts), therapy (e. g. pen inhibitors to modulate APP processing) and in the biopharmaceutical industry (e. g. as immunogens, reagents for screening chemical libraries for lead pharmacological agents, etc. ).